Humacyte Inc. (HUMA)
1.90
-0.11 (-5.47%)
At close: Mar 28, 2025, 3:59 PM
1.93
1.58%
After-hours: Mar 28, 2025, 07:56 PM EDT
-5.47% (1D)
| Bid | 1.82 |
| Market Cap | 244.47M |
| Revenue (ttm) | 11.63M |
| Net Income (ttm) | -164.72M |
| EPS (ttm) | -1.34 |
| PE Ratio (ttm) | -1.42 |
| Forward PE | -5.34 |
| Analyst | Buy |
| Ask | 1.97 |
| Volume | 11,168,300 |
| Avg. Volume (20D) | 2,819,358 |
| Open | 2.12 |
| Previous Close | 2.01 |
| Day's Range | 1.76 - 2.11 |
| 52-Week Range | 1.76 - 9.97 |
| Beta | 1.36 |
About HUMA
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without i...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 1, 2020
Employees 183
Stock Exchange NASDAQ
Ticker Symbol HUMA
Website https://www.humacyte.com
Analyst Forecast
According to 7 analyst ratings, the average rating for HUMA stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 636.84% from the latest price.
Stock ForecastsNext Earnings Release
Humacyte Inc. is scheduled to release its earnings on May 9, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago
-30.56%
Humacyte shares are trading lower after the compan...
Unlock content with
Pro Subscription
5 days ago
-13.25%
Humactye shares are trading lower after the company announced it had commenced a public offering of common stock.
